US EditionBioTech acquires Toronto-based Awakn
Summary by BusinessCloud.co.uk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BioTech acquires Toronto-based Awakn
Clinical-stage BioTech Solvonis has acquired Toronto-based Awakn, expanding its research and development pipeline. London-based Solvonis, which is focused on developing innovative medicines for the treatment of addiction and mental health disorders, is focused on alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) treatments in the short-term. The acquisition brings new therapies into its pipeline, including SVNS-001 (previousl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
